List view / Grid view
21 January 2014 | By kdm communications limited
Spanish biotechnology company Midatech Biogune is taking advantage of Syrris Atlas Potassium reactor systems to produce custom-made functionalized gold nanoparticles for medicinal use...
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
In Issue #6 2013: PAT in-depth focus, Lab Automation, Proteomics, Next Gen Sequencing, Screening in-depth focus, Microbiology...
12 December 2013 | By Merck
GRASTEK is the proposed trade name for the company’s investigational sublingual tablet for the treatment of Timothy grass induced allergic rhinitis...
18 November 2013 | By Merck
“I am excited by the results seen for MK-3475 to date as a single agent..."
9 November 2013 | By Merck
“Patients in this study who took the investigational Timothy grass sublingual allergy immunotherapy tablet showed a significant improvement in common allergy symptoms..."
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
Read the free digital version of Issue #5 2013 of European Pharmaceutical Review magazine...
23 October 2013 | By Stallergenes
Sublingual immunotherapy sales continued to grow in the 3rd quarter thanks notably to the fast adoption of Oralair® in France...
22 October 2013 | By Amancio Carnero, Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas
There is an urgent need to predict which treatment will report the most benefit to a patient with cancer. To that end, scientists are exploring any possible biomolecule in the organism that can mark each individual for its adequate treatment. If achieved, it will open a personalised medicine era.
22 October 2013 | By Mark Wade, Center for Genomic Science of IIT@SEMM
Protein-protein interactions (PPI) form the backbone of all cellular signalling networks, and aberrant PPI contribute to the pathology of several diseases. Thus, strategies to identify PPI modulators are expected to be therapeutically beneficial. However, there are very few examples of clinically approved PPI modulators, reflecting the difficulties of identifying effective…
1 October 2013 | By Merck
An abstract (# 2416) published today summarized preliminary findings from 38 patients with NSCLC treated with MK-3475...
Read the free digital version of the August / September edition of European Pharmaceutical Review magazine...
20 August 2013 | By Niklas Larsson, Linda Sundström, Erik Ryberg and Lovisa Frostne (AstraZeneca)
G protein-coupled receptors are one of the major classes of therapeutic targets for a broad range of diseases. The most commonly used assays in GPCR drug discovery measure production of second messengers such as cAMP or IP3 that are the result of activation of individual signalling pathways. Such specific assays…
Read the free digital version of the June / July edition of European Pharmaceutical Review magazine...
